Chart Review: Unresectable/Metastatic Cholangiocarcinoma Treated With Irinotecan, Capecitabine and Celecoxib

This study has been completed.

Sponsored by:	University of New Mexico
Information provided by:	University of New Mexico
ClinicalTrials.gov Identifier:	NCT00320918

Purpose

Chart Review on Patients with unresectable/metastatic cholangiocarcinoma treated in the UNM Cancer Center with a combination of irinotecan, capecitabine and celecoxib.

Condition
Cholangiocarcinoma

MedlinePlus related topics: Cancer

Drug Information available for: Irinotecan Irinotecan hydrochloride Capecitabine Celecoxib 4-(5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide

U.S. FDA Resources

Study Type:	Observational
Study Design:	Cohort, Retrospective
Official Title:	Chart Review on Patients With Unresectable/Metastatic Cholangiocarcinoma Treated in the UNM Cancer Center With a Combination of Irinotecan, Capecitabine and Celecoxib

Further study details as provided by University of New Mexico:

Biospecimen Retention: None Retained

Biospecimen Description:

Enrollment:	10
Study Start Date:	November 2005
Study Completion Date:	October 2006
Primary Completion Date:	August 2006 (Final data collection date for primary outcome measure)

Detailed Description:

As above.

Eligibility

Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No
Sampling Method:	Probability Sample

Study Population

Patients with unresectable/metastatic cholangiocarcinoma treated in the UNM Cancer Center with a combination of irinotecan, capecitabine and celecoxib.

Criteria

Inclusion Criteria:

Patients with unresectable/metastatic cholangiocarcinoma treated in the UNM Cancer Center with a combination of irinotecan, capecitabine and celecoxib.

Exclusion Criteria:

Not specified.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00320918

Locations

United States, New Mexico
University of New Mexico
Albuquerque, New Mexico, United States, 87131

Sponsors and Collaborators

University of New Mexico

Investigators

Principal Investigator:

Fa-Chyi Lee, MD

University of New Mexico

More Information

Responsible Party:	University of New Mexico - CRTC ( Fa-Chyi Lee, MD; Principal Investigator )
Study ID Numbers:	4504C
Study First Received:	April 28, 2006
Last Updated:	October 16, 2008
ClinicalTrials.gov Identifier:	NCT00320918
Health Authority:	United States: Institutional Review Board

Keywords provided by University of New Mexico:

Unresectable/metastatic cholangiocarcinoma
Cancer
Chart Review

Study placed in the following topic categories:

Cholangiocarcinoma
Capecitabine
Celecoxib
Irinotecan

Adenocarcinoma
Neoplasms, Glandular and Epithelial
Carcinoma

Additional relevant MeSH terms:

Antimetabolites
Neoplasms
Antimetabolites, Antineoplastic
Neoplasms by Histologic Type

Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Therapeutic Uses
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 16, 2009